Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1CNS 1Breast 1

Conditions

Epilepsy 3Small Cell Lung Carcinoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1

Interventions

Sirolimus 4LY3295668 erbumine 3Everolimus 3Anticonvulsants 2perampanel 1clevidipine 1brivaracetam 1Vigabatrin 1Topotecan 1Therapeutic Touch 1Temozolomide 1TAS-119 1Sulfasalazine 1Sevoflurane 1Saline Solution 1Radiotherapy 1Propofol 1Paclitaxel 1Nitrous Oxide 1Midazolam 1Memantine 1Medical Marijuana 1Lidocaine 1Levetiracetam 1Ketamine 1Immunoglobulins, Intravenous 1Glycopyrrolate 1Gabapentin 1Fluid Therapy 1Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Epilepsy × LY3295668 erbumine × Clear all
NCT04106219 2026-04-21

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Eli Lilly and Company

Phase 1 Active not recruiting
71 enrolled
CNS

Epilepsy, Neuroblastoma

NCT03898791 2021-08-05

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

Eli Lilly and Company

Phase 1 Completed
48 enrolled
Thoracic

Epilepsy, Small Cell Lung Carcinoma

NCT03955939 2020-06-01

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

Eli Lilly and Company

Phase 1 Completed
5 enrolled
Breast

Breast Neoplasms, Epilepsy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡